Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Five non-genotoxic chemicals previously demonstrated to be bladder cancer promoters in 36-week in vivo assays for carcinogenesis were reevaluated in a 20-week experiment in order to assess the summation influence of dietary uracil, a component of RNA, on the development of (pre)neoplastic lesions. The test chemicals, sodium bicarbonate, sodium L-ascorbate, sodium citrate, butylated hydroxytoluene and ethoxyquin, were mixed into the diet at concentrations of 3%, 5%, 5%, 1% and 0.8%, respectively, and administered to male F344 rats after initiation with 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in their drinking water for 4 weeks. The test chemicals were given from the 4th to the 8th and the 11th to 20th experimental weeks, uracil being administered at the level of 3% in the diet during the intervening period. Rats in the control group received only BBN and uracil. All animals were killed at week 20 and the bladders were evaluated for the occurrence of putative preneoplastic papillary or nodular (PN) hyperplasia and tumors. Significant increase in the occurrence of PN hyperplasia was observed in all groups initiated with BBN and fed uracil and test chemicals. Quantitative values for papillomas were also significantly increased except in the ethoxyquin-treated group. The results confirm that uracil given in the middle of the post-initiation stage enhances the promoting activity of chemicals and suggest that the use of this chemical might be useful to reduce the duration of current bioassays for bladder chemical carcinogens.
de Camargo
J L
JL
First Department of Pathology, Nagoya City University Medical School.
Shirai
T
T
Kato
T
T
Asamoto
M
M
Fukushima
S
S
D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002083:Butylated Hydroxyanisole / Q000633:toxicity; D002084:Butylated Hydroxytoluene / Q000633:toxicity; D002085:Butylhydroxybutylnitrosamine / Q000031:analogs & derivatives / Q000633:toxicity*; D002273:Carcinogens / Q000633:toxicity*; D004848:Epithelium / Q000187:drug effects / Q000473:pathology; D005015:Ethoxyquin / Q000633:toxicity; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D010212:Papilloma / Q000139:chemically induced / Q000473:pathology; D011230:Precancerous Conditions / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D011916:Rats, Inbred F344; D014498:Uracil / Q000633:toxicity*; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology*; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000473:pathology
D002273:Carcinogens; D002084:Butylated Hydroxytoluene; D002083:Butylated Hydroxyanisole; D002085:Butylhydroxybutylnitrosamine; C010723:N-ethyl-N-(4-hydroxybutyl)nitrosamine; D014498:Uracil; D005015:Ethoxyquin; D001205:Ascorbic Acid